Chemical Structure (Glyburide 01)
Glyburide Tablet
Product Images NDC 75834-202
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Glyburide (NDC 75834-202). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nivagen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Principal Display Panel (1.25 mg Tablet Bottle Label)
This is a description for GlyBURIDE, a tablet medication used as a treatment for diabetes. The tablets come with 1.25 mg of glyburide and the standard dosage is indicated in the literature that comes with the product. The medication should be stored between 20° to 25°C, and the container must be kept tightly closed at all times, in a place out of reach of children. The box includes 100 tablets and a child-resistant closure. There is also information regarding the manufacturer, Nivagen Pharmaceuticals, and the manufacturer's license number and address.*
Principal Display Panel (2.5 mg Tablet Bottle Label)
This is a medication called GlyBURIDE available in tablet form with the NDC code 75834-203-01. Each tablet contains 2.5 g of glyburide, USP, and is used for diabetes control. It can only be taken after consulting the accompanying literature since the dosage varies. It should be stored at 20° to 25°C (68° to 77°F) and kept away from children. The medication is manufactured by Cadila Pharmaceuticals and distributed by Nivagen Pharmaceuticals. The license number of the manufacturer is Mig. Lic. No.: G/1500. The document was issued in January 2019.*
Principal Display Panel (5 mg Tablet Bottle Label)
Glyburide is a medication used for controlling high blood sugar level by regulating insulin release from the pancreas in diabetic patients. This specific product is in the form of tablets containing 5 mg of glyburide each. The recommended storage temperature range for the tablets is 20° to 25°C with permissible temperature excursions allowed between 15° to 30°C. The medication should be kept out of reach of children and dispensed in a tightly closed and light-resistant container with a child-resistant closure as required by the USP. The manufacturer of the medication is Nivagen Pharmaceuticals, Inc. based in Sacramento, CA, and it is manufactured by Cadila Pharmaceuticals Ltd. based in Gujarat State, India. The NDC code for this product is 75834-204-01, it contains 100 tablets with the usual dosage and directions for use available in the accompanying literature. Issued in January 2019.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
